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Introduction
Gene therapy is a novel approach that can be applied
to any clinical therapeutic procedure in which nucleic
acids are introduced into cells for the purpose of treat-
ing, curing or ultimately preventing disease1. Most com-
monly, the nucleic acids involved are DNA molecules
that encode wild-type or modified gene products or
proteins. The method used to transfer the nucleic acids
into cells or tissues and the subsequent overexpression
of the encoded proteins result in the therapeutic effects.
Gene therapy can be targeted to germline (egg and
sperm) or somatic (body) cells. In germline gene therapy,
the parent’s eggs or sperms are changed with the goal
of passing on the changes to their offspring. Germline
gene therapy is not being actively investigated, at least
not in large mammals or humans. In somatic gene ther-
apy, alterations in the genetic makeup of individual
somatic cells are not passed on to the next generation.
Currently, gene therapy is solely concerned with deliv-
ering genes into somatic cells and does not involve
genetic modification of the human germline, because
this is not acceptable in most countries.
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SUMMARY
Gene therapy, which is still at an experimental stage, is a technique that attempts to correct or prevent a 
disease by delivering genes into an individual’s cells and tissues. In gene delivery, a vector is a vehicle for trans-
ferring genetic material into cells and tissues. Synthetic vectors are considered to be prerequisites for gene
delivery, because viral vectors have fundamental problems in relation to safety issues as well as large-scale 
production. Among the physical approaches, ultrasound with its associated bioeffects such as acoustic cavita-
tion, especially inertial cavitation, can increase the permeability of cell membranes to macromolecules such as
plasmid DNA. Microbubbles or ultrasound contrast agents lower the threshold for cavitation by ultrasound
energy. Furthermore, ultrasound-enhanced gene delivery using polymers or other nonviral vectors may hold
much promise for the future but is currently at the preclinical stage. We all know aging is cruel and inevitable.
Currently, among the promising areas for gene therapy in acquired diseases, the incidences of cancer and
ischemic cardiovascular diseases are strongly correlated with the aging process. As a result, gene therapy tech-
nology may play important roles in these diseases in the future. This brief review focuses on understanding the
barriers to gene transfer as well as describing the useful nonviral vectors or tools that are applied to gene delivery
and introducing feasible models in terms of ultrasound-based gene delivery. [International Journal of Gerontology
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In Taiwan, the development of gene delivery tech-
nologies is still in the very early stage. Applications of
gene therapy require a Good Manufacturing Practice
certificate by experienced researchers in medical cen-
ters, according to the guidelines from the Department
of Health (www.doh.gov.tw/EN2006/index_EN.aspx), and
need to fulfill the guidelines in terms of ethical and
safety issues. For instance, applications of gene ther-
apy are only allowed to involve somatic cells because
of ethical problems. In addition, the possible lethal re-
sponses of humans to viral vectors (gene carriers) mean
that carrier manipulation needs to be performed in 
an appropriate laboratory, such as a P1 laboratory for
adeno-associated virus carriers, a P2 laboratory for
adenovirus carriers or a P3 laboratory for retrovirus
carriers. However, these advanced laboratories are solely
located in medical centers or advanced research insti-
tutes in Taiwan. Consequently, regarding efforts to per-
form gene therapy in the future with respect to safety
in local hospitals, gene therapists need to choose appro-
priate vectors, such as nonviral vectors. Cost-benefit
analyses of gene therapy, i.e., analyses of the possibility
of causing adverse effects/expense and gaining positive
clinical effects, cannot be overemphasized before each
treatment. The central focus of this brief review is the
use of nonviral technologies and physical approaches,
especially ultrasound (US)-based gene delivery, as poten-
tial tools for clinical gene delivery. Most of the basic
technical principles regarding US are located in the sec-
tion entitled “US-based Technologies in Gene Delivery”,
and clinicians can therefore choose their own areas of
interest.
Overview of Applications in Gene Therapy
The first investigation of vascular gene transfer was
reported by Nabel et al.2, who transfected porcine
endothelial cells (ECs) ex vivo with a retrovirus encoding
the β-galactosidase gene and reintroduced the cells
into the denuded iliofemoral artery of syngeneic pigs.
Arterial segments isolated after 2 to 4 weeks contained
ECs expressing β-galactosidase, thereby indicating suc-
cessful incorporation of the transgene into the trans-
duced cells. The first federally approved clinical trial 
of somatic gene therapy for a genetic disorder was
started in the United States in September 1990. In this
trial, the adenosine deaminase gene was transferred
into the T-cells of two children with severe combined
immunodeficiency3. Although the gene therapy ended
2 years later, the integrated vector and adenosine deam-
inase gene expression in the T-cells persisted. Since
then, more than 1,000 clinical trials have taken place
worldwide. The diseases most commonly treated with
gene therapy are cancers (66.5%), cardiovascular dis-
eases (9%), monogenic diseases (8.2%), and infectious
diseases (6.6%)4.
Candidate Diseases and Target 
Therapeutic Genes
There are several promising areas for gene therapy in
genetic and acquired diseases. For acquired diseases,
cancers and cardiovascular diseases (more specifically,
peripheral artery occlusive disease [a group of diseases
caused by obstruction of peripheral arteries, mainly
resulting from atherosclerosis]5–7, restenosis8,9, in-stent
restenosis10,11, bypass graft failure12 and therapeutic
angiogenesis for myocardial ischemia13–15) are the most
explored. Among diseases related to the aging process,
such as peripheral artery occlusive disease and ischemic
heart disease, gene therapy may provide alternative
roles. Regarding monogenic diseases, hemophilia, cys-
tic fibrosis and familial hypercholesterolemia are of
importance. The identification of defective genes in
individual conditions with a view to introducing the
normal counterparts by gene therapy is a major field
of ongoing research.
Useful Vectors and General Approaches in
Gene Therapy
Gene therapy is still in the early stages of development
and remains predominantly experimental. Many fac-
tors have prevented researchers from developing suc-
cessful gene therapy techniques. The process of gene
delivery into cells for expression is known as transfec-
tion. Strictly speaking, viral vectors deliver exogenous
nucleic acids by transduction, but for ease of use the
term, transfection is used for all techniques in gene
delivery. Successful transfection relies on achieving a
biological balance between causing excessive damage
to the cell and gaining adequate access of the DNA
into the cytoplasm or nucleus. The first issue that needs
to be addressed is the gene delivery tool. Gene deliv-
ery is achieved via vehicles designated vectors, which
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deliver therapeutic genes to the patients’ target cells
or tissues. The three main categories of techniques that
have been used to deliver genes to cells or tissues in
gene therapy protocols are viral vectors (66.9%), nonvi-
ral vectors (26.6%), and physical delivery systems (1%)4.
Currently, the most frequently used vectors are viruses16,
of which the three most common are adenovirus, retro-
virus, and adeno-associated virus. Owing to their highly
evolved and specialized components, viral systems are by
far the most effective means of DNA delivery, and they
achieve high levels of both transfection efficiency (i.e.,
percentage of cells exposed to the vector that express
the transgene) and transgene expression in the trans-
fected cells. Scientists have tried to take advantage of
virus biology and manipulate viral genomes to replace
nonessential genes, particularly those necessary for viral
replication, with therapeutic genes. However, despite
their efficiency, viral vectors introduce other problems
to the body, such as toxicity and the induction of im-
mune and inflammatory responses17. Nonviral vectors
have been developed to overcome some of these hur-
dles encountered with viral vectors, particularly the
immunogenicity18. However, gene expression follow-
ing nonviral transfection is often transient and tends
to decrease rapidly within the first few days and dis-
appear within 1 week. To date, some important non-
viral alternatives that have been considered for gene
delivery are complexes of DNA with lipids or poly-
mers. In terms of physical nonviral delivery systems,
needle-free injection, electroporation and US are the
three major technologies currently under evaluation.
Once a vector has been designed, two general
approaches are used for somatic gene transfer: (1) the
ex vivo model, in which cells are isolated, genetically
modified and transplanted back into the same subject;
and (2) the in vivo model, in which genes are adminis-
tered directly to target cells in the body1.
Challenges in Gene Therapy
The death of an 18-year-old boy, Jesse Gelsinger, during
a gene therapy clinical trial in 1999 raised critical ques-
tions concerning the safety of experimental gene ther-
apy trials19. Jesse suffered from a deficiency of ornithine
transcarbamylase, a genetic defect that prevents the
correct metabolism of ammonia, and died of compli-
cations from an inflammatory response shortly after
receiving a dose of an adenovirus carrying a corrective
gene. His death illustrates the challenges in gene therapy
well and has given rise to much demanded discussion
regarding the validity of using gene delivery vectors,
especially viral vectors, and the evaluation of possible
adverse effects in animal models.
Current Gene-transfer Systems
A feasible gene therapy vector needs to meet the fol-
lowing three important criteria: safety; adequate gene
transfer efficiency; and stable and reliable expression
of the transgene (gene of interest) for an appropriate
duration for the disease under treatment. There are at
least five barriers that need to be overcome for success-
ful gene delivery, namely cell entry, endosome escape,
cytoplasmic transport and nuclear entry, in vitro and
in vivo stability, and biocompatibility. Unfortunately,
such ideal gene delivery systems are still under inves-
tigation. In the present section, nonviral vectors and
physical methods are briefly introduced. It is well known
that nonviral vectors are associated with low transfection
efficiency, especially in vivo, and more transient expres-
sion in gene delivery. However, comparisons between
them are not possible, because no reports have been
published in this regard. The important nonviral vectors
and physical approaches are summarized in Table 1 in
terms of their key mechanisms.
Nonviral Vectors
The safety concerns associated with viral vectors have
encouraged the development of nonviral vectors. Plas-
mid DNA (pDNA) delivered by nonviral methods is not
integrated into the cellular genome but maintained at
an extrachromosomal site20. The most popular materials
used in current nonviral applications include purified
pDNA, lipids (usually a mixture of cationic and neutral
lipids), and synthetic polymers.
Naked DNA
The simplest nonviral gene delivery system currently
in use in vivo is direct injection of naked pDNA. The
use of naked pDNA without any carrier vehicle is also
the safest method. However, owing to the rapid degra-
dation of naked pDNA by nucleases in the serum and
its clearance by the mononuclear phagocyte system 
in the systemic circulation, the expression levels after
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injection of naked DNA are generally limited. Although
this technique has a low delivery efficiency, it is simple
and safe with a very low risk of insertional mutagen-
esis. One of the promising approaches in this field is the
combined use of naked DNA and a physical approach
(such as electroporation) to enhance plasmid-mediated
gene expression in muscle21–24.
Lipid-based vectors
Lipid-based gene delivery, which was first reported in
1987 by Felgner et al.25, is still one of the major systems
for increasing the transfection efficiency of naked DNA.
Naked DNA forms liposomes or lipoplexes with posi-
tively charged lipids and detergents26,27, and these
positively charged lipid–DNA complexes are capable
of condensing with negatively charged DNA. Zabner 
et al.28 reported that condensed lipid–DNA complexes
appear to be 100nm or larger, at least in one dimension.
Cationic lipids and cationic polymers both share this
important property of complex formation with DNA.
Furthermore, the resulting net positive charge of
lipid–DNA complexes may facilitate fusion with the neg-
atively charged cell membrane. Endocytosis is consid-
ered to be the major mechanism for liposomes to pass
through the cell membrane28–30. Most of the liposome–
DNA complexes are intracellularly degraded by lysoso-
mal enzymes, and only 1% of the DNA enters the nucleus
where it remains extrachromosomal. Therefore, trans-
gene expression using liposomes is transient. Liposomes
are nonpathogenic with no size limit for the transgene
and are relatively cheap and easy to produce compared
with viral vectors. Although the major limitation to their
application is the poor efficiency for transfecting non-
proliferating cells, several studies have shown high levels
of transgene expression following direct administration
or injection31–33.
Synthetic polymers
Synthetic polymers have also been evaluated as nonvi-
ral DNA vehicles. The principle is based on the concept
of forming condensed DNA particles via complex for-
mation with cationic polymers, referred to as polyplexes.
The use of polycationic polymers leads to electrostatic
neutralization of the anionic charges of DNA and sub-
sequent condensation of the polynucleotide structure
of DNA, thereby protecting it against nuclease diges-
tion34,35. Furthermore, owing to the reduced dimensions
of the molecules, transport of the compact polymer–
DNA particles is facilitated through the extracellular
matrix. As a result, the cellular uptake through endo-
cytosis is enhanced.
Many polycationic molecules have been used, includ-
ing poly-L-lysine (PLL), polymethacrylate dendrimers,
polyamidoamine and polyethyleneimine (PEI). Among
these, PEI and PLL are the most common and important
molecules used as nonviral vectors.
PLL is a well-known polycation and has been used
to deliver drugs for many years. It has also been used to
condense pDNA under various salt conditions34,36–38.
The resulting PLL–DNA particles have been shown 
to be protected against DNA degradation39,40. Electron
microscopic studies have revealed that PLL–DNA com-
plexes assume a rod-like appearance with a diameter
of 15nm and a length of 109±36nm and are thus much
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Table 1. Summary of the mechanisms for important nonviral vectors and physical approaches in gene delivery
Nonviral vector Central mechanism
pDNA Endocytosis
Lipid-based vectors Endocytosis; condensation
Synthetic polymers (PEI, PLL) PLL: endocytosis, condensation
PEI: endocytosis, condensation, proton sponge
Physical approach Central mechanism in gene delivery
Needle-free injection Gene gun: high-pressure helium stream
Jet gun: high-pressure solution
Electroporation Electric pulse-induced promotion of cell membrane permeability
Ultrasound Ultrasound energy-induced promotion of cell membrane permeability (sonoporation)
pDNA = plasmid DNA; PEI = polyethyleneimine; PLL = poly-L-lysine.
smaller than lipoplexes (Figure 1). The poor circulatory
half-lives of PLL–DNA complexes, typically shorter than
3 minutes, limit their use in vivo41–44. In general, PLL
and PLL–DNA complexes have been reported to exhibit
low immunogenicities41,45.
Among the cationic polymers, PEI has been the most
commonly used for gene delivery. Polycationic PEI is
receiving much attention because of its characteristic
of condensing DNA with an intrinsic endosomolytic
activity46. Completely condensed PEI–DNA complexes
are more homogenous and smaller in diameter than
lipospermine (a cationic lipid)–DNA complexes (20–40
vs. 50–70 nm; Figure 1)47.
The most prominent feature of PEI is its extremely
high cationic charge density. Because every third atom of
the PEI molecule is a nitrogen atom that can be proton-
ated in the endosomal pH range48,49, PEI has the ability
to capture protons that are pumped into endolysosomes,
thereby acting as a proton sponge. This effect is pre-
sumably followed by passive chloride influx into the
endosomes, which leads to osmotic swelling and dis-
ruption of the endosomes and permits the escape of the
endocytosed PEI–DNA complexes. However, PEI is highly
cytotoxic. Factors influencing its cytotoxicity include its
molecular weight, incubation time, cation concentra-
tion and density of cationic groups50–52. Although the
toxic effects of PEI on cells can be reduced by conjuga-
tion with other polymers, such as PEG53, this conjuga-
tion is not sufficient to completely solve the cytotoxicity
problem.
Physical Approaches
To date, there have been three major physical ap-
proaches to gene delivery, namely needle-free injection,
electroporation, and US.
Needle-free injection
Two devices have been developed that allow gene
delivery by injection without needles. The first device,
referred to as a “gene gun”54, uses a high-pressure helium
stream to directly deliver DNA coated onto gold particles
into the cytoplasm. The efficiency of the gene gun is
variable, and the duration of the expression is transient.
The relative advantages of the gene gun over some viral
vectors are that it can be used to transfer genes into
nondividing cells and the DNA–gold beads are cheap
and easy to prepare. Gene gun delivery into the skin is
a promising alternative to the injection of naked pDNA
into muscle for genetic vaccinations55.
The second device, called a “jet gun”, uses a DNA-
containing solution under high pressure for delivery
into interstitial spaces. Jet injections of naked DNA
may provide an option for keratinocyte gene therapy
in the future56.
Electroporation
Since 1982, the use of electric pulses for cell electropo-
ration has been applied to introduce foreign DNA into
prokaryotic and eukaryotic cells in vitro57. Electropo-
ration uses electrical fields to create transient pores in
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30 nm
200 nm
Figure 1. Electron micrographs of poly-L-lysine–DNA (right) and partially condensed polyethyleneimine–DNA (left) complexes.
With permission from reference 47.
the cell membrane that allow the entry of normally
impermeable macromolecules into the cytoplasm. To
date, electroporation has been used for in vivo studies
of gene transfer into skeletal muscle21,58.
US-based Technologies in Gene Delivery
US waves are defined as mechanical sound waves with
frequencies above the audible sound range of humans,
generally about 20 kHz59.
The principle of piezoelectricity is commonly applied
to generate US waves. Piezoelectric materials can be
used as ultrasonic transducers for medical purposes.
The application of a rapidly alternating potential across
a piezoelectric crystal induces corresponding alternating
dimensional changes, consequently converting electri-
cal energy into sound waves. The direction of US wave
propagation is the same as the direction of oscillation.
The medium that the sound wave propagates through
is alternately compressed (“compression” or “high pres-
sure” zone; Figure 2) and stretched (“rarefaction” or “low
pressure” zone; Figure 2), resulting in pressure variations
in the medium.
Bioeffects of US
The physical effects of US have been studied in vitro
and in vivo, and they can be classified in two principal
groups, i.e., thermal and mechanical. The mechanical
group includes acoustic cavitation60, acoustic microstre-
aming61, and radiation pressure. Among these, acoustic
cavitation is thought to be the most important bio-
effect. Briefly, as the US waves propagate through the
medium, the characteristic compression and rarefaction
cause microscopic gas bubbles in the tissue fluid to
contract and expand, respectively. Two types of cavita-
tion are recognized. Gas body activation62,63 and sta-
ble cavitation are terms used to describe bubbles that
oscillate in diameter with the passing pressure variations
of the sound wave. Generally, in gas body activation,
only a relatively low level of US intensity is demanded
to activate a preexisting gas body. Inertial cavitation63
or transient cavitation occurs when the bubble oscilla-
tions are so large that the bubbles finally implode vio-
lently, producing pressure discontinuities (shock waves),
free radicals, extremely high localized temperatures
(at least 5,000 K), pressures (up to 1,200 bars) and light
(sonoluminescence).
Fundamental parameters of US
The intensity of the US beam is one of the crucial
parameters that determine the rate and extent of the
thermal and nonthermal effects. Intensity (W/cm2) refers
to the amount of energy contained in a wave as it passes
through any one point. More recently, the mechanical
index (MI)64,65 has come into use as an indicator or pre-
dictor of possible biological responses to cavitation-
related bioeffects.
The MI is defined as:
where f is the driving frequency in MHz and P is the
peak rarefactional (negative) pressure in MPa (Figure 2).
P is the amount of negative acoustic pressure within 
a US field and is often used to describe the likelihood
MI P
f
=
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Figure 2. Schematic representation of a continuous ultrasound wave. The peak ultrasound rarefaction pressure (pressure
minimum) is proportional to the mechanical index.
of causing a nucleus to undergo inertial cavitation in
response to a series of US pulses.
Applications of US in gene delivery
It is well known that ultrasound exposure (USE) can
induce transient pore formation in the cell mem-
brane66–69, referred to as sonoporation, which allows
proteins and other macromolecules access into the cells.
Sonoporation can be regarded as similar to the promo-
tion of membrane permeability induced by US energy.
Although researchers believe that nonthermal bioef-
fects (cavitation) play a crucial role in US-induced gene
expression, the exact mechanism of which remains
under investigation.
In vitro applications of US in gene delivery
Naked pDNA is the simplest nonviral vector. However,
the phosphate groups on the deoxyribose rings of DNA
confer a net negative charge on the molecule, thereby
hampering its potential for electrostatic interaction with
the anionic lipids in the cell membrane and causing 
a very low cellular uptake. Disadvantages for systemic
gene delivery with naked DNA have also been found,
because pDNA vectors can be rapidly degraded and
neutralized by endogenous deoxyribonucleases. There-
fore, it is reasonable to combine naked pDNA delivery
with other methods to improve the transgene effi-
ciency. In 1987, Fechheimer et al.70 first demonstrated
that US had potential as a tool for pDNA delivery into
murine fibroblasts. The first major investigation in this
field came in 1996, when Kim et al.71 studied the poten-
tial use of USE as a novel transfection method for lab-
oratory use. The maximal transfection rate was 2.4% 
of surviving primary chondrocytes, while ~50% of the
exposed cells died. Lawrie et al.72 used a custom-built
US transducer to expose cultures of porcine vascular
smooth muscle cells (VSMCs) and ECs to very low intensity
1-MHz US (MI, 0.1; 0.4 W/cm2). USE for 1 minute was
found to enhance luciferase transgene expression in
porcine VSMCs by 7.5-fold and 2.4-fold at 48 hours post-
transfection compared with naked plasmid transfection
and lipofection, respectively.
In 2005, Feril et al.73 investigated the effects of
US (1 MHz) on liposome-mediated transfection, using
three types of liposomes (L1, L2 and L3) containing
dioleoylphosphatidylethanolamine and cholesterol at
varying ratios. HeLa cells were treated with liposome
(L1 or L2)–DNA complexes containing the LUC plasmid
for 2 hours before USE (0.5 W/cm2; 1 MHz for 1 minute).
LUC expression at 24 hours after USE was significantly
increased by 2.4-fold with L1 and 1.7-fold with L2. The
important results described above suggest that US can
enhance gene delivery, possibly via cavitation, even with-
out adding microbubble echo contrast agents (MECAs).
In 2007, Deshpande et al.74 performed US-assisted
in vitro reporter gene transfection and found that US
sonication alone increased transfection by up to 18-
fold, while DNA complexed with PEI increased trans-
fection by up to 90-fold, compared with a control DNA
group. In addition, the combination of US and PEI syn-
ergistically increased transfection by up to 200-fold,
resulting in a transfection efficiency of 34%.
MECAs and their applications in gene delivery
The concept of US contrast imaging was introduced in
the 1960s and has significantly extended the use of US
imaging during recent years owing to dramatic improve-
ments in the stability, circulation time and echogenicity
of MECAs. Because of their capability to increase the US
backscatter signal from blood with minimal toxicity,
MECAs have been applied in combination with conven-
tional two-dimensional and Doppler imaging for diag-
nosing diseases and creating better images of the states
of organs.
The ideal MECAs should be nontoxic, intravenously
injectable, capable of crossing the pulmonary capil-
lary bed after a peripheral injection, and sufficiently
stable to achieve enhancement for the duration of the
examination. They are typically gas-encapsulated micro-
bubbles of around 1–10 µm in diameter75,76. Contrast
agents have a gas core that is filled with air or a higher
molecular weight substance, such as perfluoropropane,
with a lower aqueous solubility. The surrounding shell
can be stiff (e.g., denatured albumin) or more flexible
(lipids or phospholipids), and the shell thickness can vary
from 10–200 nm. Microbubbles have been shown to
lower the energy threshold for cavitation by US energy
and to have the potential of enhancing cavitation77.
When US interacts with MECAs, leading to cavitation,
pDNA and fragments of the microbubbles are driven
across cell membranes into the target cells78. Conse-
quently, acoustic cavitation plays a critical role in US-
assisted gene delivery.
In vivo applications of US in gene delivery
Recently, US gene delivery has been applied in several
tumor cell lines, as well as in ECs and VSMCs72,79. In
terms of transdermal delivery of various molecules 
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in vitro and in vivo, US has shown enhancing effects for
in vitro and in vivo delivery of insulin80–82, glucose83,84
and heparin85.
Although these are promising in vitro findings, US-
based gene delivery is still in its infancy. Since 1996,
there have been several in vivo investigations concerning
US-assisted gene delivery with or without microbubbles.
The in vivo studies of US-assisted gene delivery are
summarized in Table 268,69,74,86–104.
Conclusion
At present, there are two main reasons why gene ther-
apy has not globally succeeded in the clinical setting,
namely inefficient delivery of the gene of interest to
its correct sites of action and safety concerns regarding
some viral-based vectors that are 1–3 orders of magni-
tude more efficient than conventional nonviral tech-
niques for gene delivery in vivo. Many gene delivery
methods, such as liposome-mediated transfection, are
much less efficient in vivo than in vitro. US has several
potential advantages over other techniques, particu-
larly in that it can be focused and therefore targeted
toward specific and, if necessary, deep locations within
the body. US gene delivery has been urged as an applica-
ble tool because of its bioeffects, especially cavitation105.
Last but not least, in efforts to further improve the
level of transgene expression, targeted gene delivery
may be one of the promising methods that will work
through US. In this regard, it would be feasible to design
targeted MECAs that can selectively bind to areas of
interest in tissues or the body for either diagnostic or
therapeutic purposes. These active targeting strategies
can be achieved by the development of targeted micro-
bubbles with antibodies or peptides attached to their
shells106–109. As a result, targeted microbubbles with a
specific ligand for the receptors expressed in the diseased
area can be applied for either US imaging or poten-
tially therapeutic purposes via US-induced cavitation.
Theoretically, it should also be possible to load micro-
bubbles with genetic material that is already condensed
by polymers or liposomes or to modify the surface of the
microbubbles. The important steps required to develop
this technique will be to load ligand-modified MECAs
with polymer/liposome-condensed genetic material
(such as pDNA) without compromising their stability
and to eliminate the cytotoxicity in vitro and in vivo.
Such “smart” microbubbles may be applied as specific
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contrast agents for US to improve diagnosis, and also
as therapeutic agents in US-based gene delivery in
clinical settings.
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